A Comparison of Dapsone and Trimethoprim-Sulfamethoxazole in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS
Launched by JACOBUS PHARMACEUTICAL · Aug 30, 2001
Trial Information
Current as of March 23, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- • Exclusion Criteria
- Concurrent Medication:
- Excluded:
- • Requirement for other medications found to be effective in the treatment of Pneumocystis carinii pneumonia (PCP) (i.e., DFMO, pyrimethamine, and sulfadiazine).
- Patients with the following are excluded:
- • History of allergic reaction to dapsone.
- • Requirement for other medications found to be effective in the treatment of Pneumocystis carinii pneumonia (PCP) (i.e., DFMO, pyrimethamine, and sulfadiazine).
- • Patients subsequently found to be glucose-6-phosphate dehydrogenase (G6PD) positive will be withdrawn from the study and treated with another regimen.
- Prior Medication:
- Excluded:
- • Requirement for other medications found to be effective in the treatment of Pneumocystis carinii pneumonia (PCP) (i.e., DFMO, pyrimethamine, and sulfadiazine).
- • Patients who are glucose-6-phosphate dehydrogenase (G6PD) positive will be withdrawn from the study and treated with another regimen.
- • Hospitalized patients with first episode of Pneumocystis carinii pneumonia (PCP) documented by GIEMSA or methenamine stain.
- * Patients must:
- • Be willing and able to give informed consent.
- • Be expected to survive 1 week without therapy.
- • Have less than 48 hours of treatment for Pneumocystis carinii pneumonia (PCP) for this episode.
About Jacobus Pharmaceutical
Jacobus Pharmaceutical is a specialized biopharmaceutical company dedicated to advancing innovative therapies for rare and complex diseases. With a strong focus on research and development, Jacobus is committed to improving patient outcomes through the development of novel treatments that address unmet medical needs. The company prides itself on its collaborative approach, working closely with healthcare professionals, regulatory agencies, and patient advocacy groups to ensure that its clinical trials are designed to meet the highest standards of safety and efficacy. Through its rigorous scientific methodologies and commitment to excellence, Jacobus Pharmaceutical strives to make a meaningful impact in the lives of patients and their families.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Princeton, New Jersey, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
Similar Trials